DENVER, Feb. 14 /PRNewswire-FirstCall/ --
Accelr8 Technology Corporation (OTC Bulletin Board: ACLY) announced the
introduction of high-performance microtiter plates at the Association of
Biomolecular Resource Facilities Annual Meeting in Denver. The new products
join the company's line of high-performance OptArray(TM) microarraying slides.
The plates and slides both feature the company's proprietary OptiChem(TM)
activated surface chemistry.
Accelr8 developed the new products in cooperation with Greiner Bio-One
GmbH, a German manufacturer of high quality microtiter plates. Under the
production agreement, Accelr8 supplies Greiner with OptiChem-coated glass
plates. Greiner then bonds the coated glass to their bottomless polystyrene
microtiter plate and packages the finished product.
The new products are the first to support high performance microarraying
applications in the microplate format. Accelr8's early entry into this
application space provides an excellent opportunity to capitalize on industry
experts' belief that plate-based microarraying is about to provide a new level
of interest in gene and protein arraying. Accelr8's product launch is
well-timed, as instrument makers are supporting this industry trend by
introducing high-volume arraying and plate scanning capabilities. The new
plates close a gap in the rollout of plate-based arraying, leveraging the
large investments in high throughput plate-handling robotic systems owned by
drug discovery laboratories.
According to Thomas V. Geimer, Accelr8's CEO and Chairman, "The new
product line takes us into specialty areas of the established market for
microtiter plates. We're one of the first companies to bring high-performance
microarraying to the plate format. OptiChem(TM) delivers the same benefits on
a plate as with our OptArray(TM) glass slides. For example, in the area of
drug discovery, we believe that our advanced microplate technology will
significantly improve data quality and shorten the time to results." He
continues, "We're also particularly pleased with our relationship with Greiner
Bio-One. They are a leading global supplier of microtiter plates and other
laboratory products, and they enjoy a reputation for high quality and
excellent service. This relationship demonstrates our commitment to work with
market leaders to establish Accelr8's technology in life sciences markets."
Certain statements in this news release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Statements regarding future prospects and developments are based
upon current expectations and involve certain risks and uncertainties that
could cause actual results and developments to differ materially from the
forward-looking statement, including those detailed in the company's filings
with the Securities and Exchange Commission.
SOURCE Accelr8 Technology Corporation